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This study was aimed to evaluate the effects of celastrol, a natural compound with
multiple bioactivities, on multiple sclerosis and optic neuritis (ON) in rat experimental
autoimmune encephalomyelitis (EAE). EAE was induced in Sprague Dawley rats
using myelin basic protein, and the animals received daily intraperitoneal injections of
celastrol or vehicle for 13 days. The EAE rats showed abnormal neurobehavior and
inflammatory infiltration and demyelination in the spinal cord. Significantly upregulated
mRNA expression of pro-inflammatory cytokines interferon-γ and interleukin-17 and
downregulated anti-inflammatory cytokines interleukin-4 were found in the spinal cord of
EAE rats. In the study of ON, severely inflammatory responses like in the spinal cord were
also seen in the optic nerve, as well as obvious microgliosis. Furthermore, activation of
nuclear factor kappa-B and upregulated inducible nitric oxide synthase was observed
in the optic nerve. In addition, apoptosis of retinal ganglion cells and dysregulation of
apoptotic-associated proteins in the optic nerve were found in EAE rats. Treatment of
celastrol potently restored these changes. In most of the indexes, the effects of high
dose of celastrol were better than the low dose. Our data conclude that administration
of celastrol attenuates multiple sclerosis and ON in EAE via anti-inflammatory and
anti-apoptotic effects. These findings provide new pre-clinical evidence for the use of
celastrol in treatment of multiple sclerosis.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative diseases characterized
by demyelination in the central nervous system (CNS; Compston and Coles, 2002). MS is a
major cause of neurological dysfunction among young adults worldwide (Bashir and Whitaker,
2002). Until now, the etiology of MS is not completely revealed, but T- and B-cells mediated
immune attack is considered to contribute to neuronal damage in the CNS (Lucchinetti et al.,
2000; Compston and Coles, 2002). Optic neuritis (ON), inflammation of optic nerve, usually refers
to the acute optic neuropathy that results from focal inflammation associated with demyelination
(Soderstrom, 2001). ON is the early diagnostic sign in approximately 20% of MS patients, and about
70% patients develop ON during the course of MS (Sorensen et al., 1999; Toosy et al., 2014; Graham
and Klistorner, 2016). In addition, most of patients with monosymptomatic ON eventually develop
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clinically definite MS, and the morbidity increases with years
[reviewed in (Soderstrom, 2001)]. In clinical routines, short-
term administration of high dose of corticosteroids is used
for relieving acute or subacute MS and ON, but long-term
use of corticosteroids is not recommended for its adverse
effects and much less impact on recovery. Other Food and
Drug Administration (FDA)-approved drugs such as interferon,
Natalizumab, Mitoxantrone, etc., also have limitation in clinical
use because of their serious side effects (Kleinschmidt-DeMasters
and Tyler, 2005; Marriott et al., 2010). Therefore, to develop novel
compounds those target the clinical disease process including ON
is necessary.
Experimental autoimmune encephalomyelitis (EAE) is the
most commonly used animal model of MS (Wekerle et al., 1994).
This model can mimic several symptoms of the MS in
human, such as the inflammation induced by T- and B-cells,
demyelination, and optic nerve damage (Storch et al., 1998;
Meyer et al., 2001; Das et al., 2013). Apoptotic cell death of retinal
ganglion cells (RGCs) occurs early in the process of EAE (Meyer
et al., 2001; Fairless et al., 2012). Myelin proteins such as myelin
oligodendrocyte protein (MOG), myelin basic protein (MBP) and
proteolipid protein are used for EAE model establishment in
rodents. In the present study, Sprague Dawley (SD) rats were
immunized by MBP and the neurological function and damages
to spinal cord and optic nerve were observed.
Celastrol is a quinone methide triterpenoid extracted from
traditional Chinese medicine Celastrus orbiculatus, C. aculeatus,
Tripterygium wilfordii (Thunder God Vine) and other plants
of the Celastraceae family (Venkatesha and Moudgil, 2016).
Numerous studies demonstrated the pharmacological effects of
celastrol on various diseases, including autoimmune diseases,
chronic inflammation, neurodegenerative diseases, and many
types of cancer (Allison et al., 2001; Salminen et al., 2010;
Kannaiyan et al., 2011). Specifically, celastrol showed prominent
effects in inflammation control and immunosuppression.
Celastrol has been demonstrated to alleviate arthritis in various
animal models through regulating the production of pro-
inflammatory cytokines and the function of immune cells
(Venkatesha et al., 2011; Cascao et al., 2012; Astry et al., 2015).
In China, T. wilfordii tablet is approved by China Food and
Drug Administration (CFDA) for rheumatoid arthritis. Recently
studies on EAE animals reported that celastrol may have ability
to attenuate MS (Abdin and Hasby, 2014; Wang et al., 2015). In
these studies, celastrol was found to regulate Th17 responses,
balance the pro- and anti-inflammatory cytokines via modulating
Th1 and Th2 responses, and downregulate nuclear factor kappa-
B (NF-κB) expression. In the present study, the effect of celastrol
on MS was evaluated in EAE rats. Besides the neuronal function
and inflammatory responses in spinal cord, inflammation in
optic nerve and RGC damage were tested as well.
MATERIALS AND METHODS
Animals
Male SD rats (8–10 weeks, 180∼200 g, the Experimental Animal
Centre of Harbin Medical University, Harbin, China) were
maintained under a 12-h light/dark cycle with free access to water
and food. All animal procedures were approved by the Ethics
Committee of Harbin.
EAE Induction and Celastrol
Administration
Rats were randomly divided into four groups: (1) control; (2)
EAE; (3) EAE + celastrol 1 mg/kg; and (4) EAE + celastrol
2 mg/kg. EAE were induced in the rats by immunization with
50 µg MBP (GL Biochem Ltd., Shanghai, China) and 1 mg/ml
mycobacterium tuberculosis emulsified in 100 µL complete
Freund’s adjuvant (CFA). Rats in the control group received
equal amount of vehicle. Rats in the celastrol groups were
intraperitoneally injected daily with indicated dose of celastrol
(Figure 1, Aladdin, Shanghai, China) for 13 days. Control and
EAE rats received the same amount of 1% dimethyl sulfoxide
(DMSO). Neurological sign was monitored daily and was scored
according to the following scale: 0, no clinical signs; 1, loss
of tail tone (limp tail); 2, waddling gait with tail weakness
(ataxia); 3, moderate hindlimb paralysis; 4, tetraparesis; and
5, moribund stage. All the rats were sacrificed at day 14 and
the spinal cord tissue in C4-T1 vertebra and optic nerve were
collected.
Histological Examination
The spinal cord tissues were fixed in 4% paraformaldehyde for
24 h, embedded in paraffin and cut into 5-µm thickness sections.
Haematoxylin and eosin (H&E) staining were used to evaluate
the inflammatory cell infiltration and pathological changes in
spinal cords. Luxol fast blue (LFB) staining was used to examine
demyelination. After being cleared with xylene and hydrated in
graded ethanol, the sections were stained with haematoxylin and
eosin or LFB (Solarbio Science & Technology, Beijing, China)
using standard protocols. The histological changes were observed
under a light microscopy (DP73; Olympus, Tokyo, Japan).
Histopathological changes were scored by two independent
FIGURE 1 | Chemical structure of celastrol.
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investigators according to the standards used in previous study
(Liu et al., 2014) and the averages were used as final scores.
Terminal Deoxynucleotidyl
Transferase-Mediated dUTP Nick End
Labeling (TUNEL)
The optic nerves were fixed in 4% paraformaldehyde for
24 h, embedded in paraffin and cut into 5-µm thickness
sections. The sections were dewaxed and stained using
Terminal Deoxynucleotidyl Transferase-Mediated dUTP
Nick End Labeling (TUNEL kit; Roche Diagnostics, Mannheim,
Germany) following the manufacturer’s protocol. Sections were
counterstained with hematoxylin and observed under the light
microscope (DP73, Olympus, Tokyo, Japan).
Immunofluorescence Staining
Dewaxed optic nerve sections were boiled in 0.1 M sodium
citrate buffer for 10 min using a microwave oven to perform the
antigen retrieval. The sections were then blocked in goat serum
for 30 min at room temperature and incubated in primary anti-
CD11b antibody (1:100, ab1211, Abcam, Cambridge, UK) at 4◦C
overnight. After being washed in PBS, Cy3- conjugated secondary
antibodies (goat anti-mouse, 1:200; Beyotime) were applied for
60 min at room temperature in darkness. Fluorescent labeling
was visualized under a fluorescence microscope (BX53, Olympus,
Tokyo, Japan).
RNA Isolation and Quantitative
Real-Time PCR
Total RNA from the spinal cord tissue and optic nerve
was isolated using a RNA simple Total RNA Kit (Tiangen,
Beijing, China) according to the manufacturer’s protocol.
Complementary DNA was reverse-transcribed from the
total RNA from each sample and oligonucleotide primer
using super M-MLV (BioTeke, Beijing, China). Quantitative
real-time PCR reactions were performed on the synthesized
cDNA using 2 × Power Taq PCR Master Mix (BioTeke)
and SYBR Green (Solarbio Science & Technology) on an
Exicycler 96 real-time quantitative thermal block (Bioneer,
Daejeon, Korea). Results were analyzed using 2−11Ct method
and represented as fold changes of β-actin. The primers
used in the study are listed as follows: interferon-γ (INF-γ),
forward: 5′-GCCCTCTCTGGCTGTTACT-3′, reverse: 5′-
TTTGCCAGTTCCTCCAGATA; interleukin (IL)-17, forward:
5′-CTACCTCAACCGTTCCACT-3′, reverse: 5′-CTTCTCAGGC
TCCCTCTTC-3′; IL-4, forward: 5′-TGATGTACCTCCGTGCTT
GA-3′, reverse: 5′-ATTTCCCTCGTAGGATGCTT-3′; IL-5,
forward: 5′-AGGCTTCCTGTTCCTACTC-3′, reverse: 5′-TC
CATTGCCCACTCTGTA-3′; TNF-α, forward: 5′-TGGCGTGT
TCATCCGTTCT-3′, reverse: 5′-CCACTACTTCAGCGTCTC
GT-3′; IL-1β, forward: 5′-TCCAGTCAGGCTTCCTTGTG-3′,
reverse: 5′-CGAGATGCTGCTGTGAGATT-3′; inducible nitric
oxide synthase (iNOS), forward: 5′-CTAGACCTCAACAA
AGCTCTC-3′, reverse: 5′-GAAGAACAATCCACAACTCGC-3′;
β-actin, forward: 5′-GGAGATTACTGCCCTGGCTCCTAGC-3′,
reverse: 5′-GGCCGGACTCATCGTACTCCTGCTT-3′.
Western Blotting Analysis
The spinal cord tissues and optic nerves were homogenized
in cooled RIPA buffer supplement with phenylmethanesulfonyl
fluoride (Beyotime) on ice. The homogenate was centrifuged
at 15,000 g for 10 min at 4◦C and the supernatants were
collected. Nuclear and cytosolic proteins were extracted using
a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime)
according to the manufacturer’s protocol. Concentration of the
protein was determined using a Bicinchoninic Acid (BCA)
Protein Assay Kit (Beyotime). Equal amount of proteins in
each sample was separated on 10% SDS-PAGE and transferred
onto polyvinylidene fluoride membranes (Millipore, Billerica,
MA, USA). After being blocked with 5% non-fat dry milk
(w/v), the membranes were incubated in primary antibodies at
4◦C overnight. After washing, the membranes were incubated
with horseradish peroxidase conjugated secondary antibody
(Beyotime) for 45 min at 37◦C. The membranes were then
reacted with ECL reagent (Beyotime) and exposed to Fuji Rx
100 X-ray film (Fuji Photo Film, Tokyo, Japan) in darkness. The
gray values of the blots were analyzed using Gel-Pro-Analyzer
(Media Cybernetics, Bethesda, MD, USA). The following primary
antibodies were used in the present study: Bcl-2, Bax, NF-κB
p65, iNOS (Boster, Huhan, China), cleaved-caspase3, cleaved-
poly ADP-ribose polymerase (PARP; Abcam), IκBα, p-p65ser536,
Histone H3 (Bioss, Beijing, China), and β-actin (Santa Cruz
Biotechnology, Inc., Dallas, TX, USA).
Statistical Analysis
Data were represented at means ± SD. Statistical analysis was
performed using SPSS 19.0 software (IBM, New York, NY, USA).
Results of pathological scores were analyzed using Kruskal–
Wallis test followed by Nemenyi test. Other results were analyzed
using one-way analysis of variance (ANOVA) followed by Fisher’s
least significant difference (LSD) test. A P value < 0.05 was
considered statistical significance.
FIGURE 2 | Treatment of celastrol attenuates neurological severity of
experimental autoimmune encephalomyelitis (EAE) rats. Neither low nor
high dose of celastrol delayed the onset of EAE, but both of the dosages
decreased neurologic severity of EAE. Data were shown as mean ± SD.
(n = 5). ∗∗P < 0.01 versus control group, ##P < 0.01 versus EAE group.
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RESULTS
Celastrol Alleviates EAE
In the present study, the effects of celastrol on EAE complicated
ON were evaluated on EAE rats. Low and high dosages of
celastrol were intraperitoneally administrated immediately after
establishment of the model. As illustrated in Figure 2, rats
showed the first neurologic sign at day 10 (1.4 ± 0.5), which
was similar to that obtained in previous studies (Samuvel et al.,
2015). The neurologic score rapidly increased in the EAE group
in the following days and reached 3.6 ± 0.5 at day 13. The scores
in the two celastrol treated groups were also increased at day 10
but underwent markedly slower increasing rate in the following
days. At day 13, the neurological score of rats treated with low
dosage of celastrol was 2.0± 0.7, and the score in the high dosage
group was 1.6 ± 0.5. Both of them were significantly lower than
that in the EAE group (P < 0.01). This result indicates that
although treatment of celastrol does not delay the onset of EAE,
it dose-dependently attenuates EAE severity in rats.
Celastrol Attenuated Inflammatory
Infiltration and Demyelination in Spinal
Cords of EAE Rats
The rats were sacrificed on day 13 and the spinal cords
were collected for histological examination. The results of
H&E (Figures 3A,B) and LFB (Figures 3C,D) staining showed
markedly inflammatory cells infiltration and demyelination in
EAE rats. Treatment of celastrol significantly decreased the
inflammatory infiltration and attenuated the demyelination. The
pathological scores of high dosage of celastrol were lower than
that of low dosage but did not reach significant.
Celastrol Inhibited Production of
Cytokines in Spinal Cords of EAE Rats
In EAE and MS, IFN-γ and IL-17 contribute to inflammation
and myelin damage (El-Behi et al., 2011; Yan et al., 2012; Segal,
2014) and IL-4 is involved in the recovery of the disease (Payne
et al., 2012). The mRNA expression of Th1/Th17 cytokines IFN-
γ and IL-17 and Th2/Treg cytokines IL-4 was determined by
quantitative real-time PCR. As shown in Figure 4, significant
increases of IFN-γ and IL-17, and a significant decrease of IL-
4 were observed in the EAE group compared to the control
group (P< 0.05). Treatment of celastrol markedly downregulated
the mRNA expression of IFN-γ and IL-17 and upregulated the
mRNA expression of IL-4, with a more profound effect in the high
dosage group compared to the low dosage group (P < 0.01).
Celastrol Inhibited Production of
Cytokines and Microgliosis in Optic
Nerve of EAE Rats
In the optic nerve of EAE rats, we found the markedly
upregulated mRNA expression of Th1/Th17 cytokines INF-
γ, IL-1β, TNF-α and IL-17 (Figure 5A) and downregulated
expression of Th2 cytokine IL-4. In line with the observations
in the spinal cord, treatment of celastrol significantly diminished
Th1/Th17 cytokines expression and enhanced IL-4 expression.
The efficacy of high dosage was better than low dosage of celastrol
(P < 0.01).
The effect of celastrol on microgliosis in optic nerve
was evaluated as well. The optic nerve sections were
immunofluorescence-stained with CD11b, a biomarker of
activated microglia (Figure 5B). Acute EAE rats showed a
notable increase of CD11b-positive areas, which indicated the
occurrence of microgliosis. In contrast, treatment of celastrol
exhibited markedly reduced microgliosis compared with EAE
rats.
Celastrol Inhibited Expression of iNOS
and Activation of NF-κB in Optic Nerve of
EAE Rats
The expression of inflammation-associated protein iNOS, the
enzyme responsible for nitric oxide production, and the changes
of proteins in NF-κB signaling pathways were investigated in EAE
FIGURE 3 | Treatment of celastrol suppressed histopathological alterations and demyelination in spinal cords of EAE rats. H & E (A) and Luxol fast blue
(LFB; C) staining showed that celastrol attenuated inflammatory infiltration and demyelination in spinal cord of EAE rats, inflammatory (B) and demyelination (D)
scores were significantly lowered in both low and high dosages of celastrol groups. Scale bars: 100 µm. Data were shown as mean ± SD. (n = 5). ∗∗P < 0.01
versus control group, ##P < 0.01 versus EAE group.
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FIGURE 4 | Celastrol regulated production of cytokines and activation of NF-κB in spinal cords of EAE rats. Celastrol dose-dependently downregulated
the mRNA expression of INF-γ (A) and IL-17 (B) but upregulated IL-4 (C) in spinal cord of EAE rats. Data were shown as mean ± SD, n = 5. ∗∗P < 0.01 versus
control group, ##P < 0.01 versus EAE group, ††P < 0.01 versus low dosage of celastrol group.
FIGURE 5 | Celastrol inhibited production of cytokines and microgliosis in optic nerve of EAE rats. Celastrol dose-dependently downregulated the mRNA
expression of INF-γ, IL-1β, TNF-α and IL-17 but upregulated IL-4 (A) in optic nerve of EAE rats. The expression of CD11b was decreased after treatment of celastrol
(B). Scale bar: 50 µm. Data were shown as mean ± SD, n = 5. ∗∗P < 0.01 versus control group, ##P < 0.01 versus EAE group, ††P < 0.01 versus low dosage of
celastrol group.
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FIGURE 6 | Celastrol inhibited inducible nitric oxide synthase (iNOS) expression and activation of NF-κB in optic nerve in EAE rats. (A) IHC staining of
iNOS in optic nerve. (B) Quantification of iNOS-positive areas. (C) Quantitative real-time PCR analysis of iNOS expression. (D) Western blot analysis of iNOS
expression. (E–G) Western blot analysis of IκBα, p65 and p-p65 expression, respectively. Treatment of celastrol reduced expression of iNOS and inhibited the
activation of NF-κB in optic nerve in EAE rats. Scale bar: 100 µm. Data were shown as mean ± SD, n = 5. ∗∗P < 0.01 versus control group, ##P < 0.01 versus EAE
group, ††P < 0.01 versus low dosage of celastrol group.
and celastrol treated rats. The mRNA and protein expression
levels of iNOS were dramatically enhanced in EAE rats, and
were markedly decreased by celastrol (Figures 6A–D). Immune-
staining of iNOS showed the similar pattern with that in Western
blot analysis. NF-κB plays a crucial role in the inflammatory
process. As a transcription factor, NF-κB leads to production
of numerous inflammatory cytokines when it is activated.
Therefore, it has become a potential therapeutic target for some
inflammatory diseases. In the present study, we investigated the
changes in levels of IκBα, phosphor-NF-κB p65 and nuclear
NF-κB p65 in the optic nerve (Figures 6E–G). The results of
Western blot analysis demonstrated that IκBα was significantly
downregulated and the expression levels of p-p65 and nuclear
p65 were upregulated in the optic nerve of EAE group compared
to normal control group. Treatment of celastrol restored these
changes in a dose-dependent manner.
Celastrol Attenuates Ganglion Cells
Apoptosis in the Retina of EAE Rats
We then sought to determine whether ganglion cell death was
inhibited in the retina of acute EAE animals after treatment
with celastrol. Results of TUNEL staining demonstrated that in
the RGC layer, numerous TUNEL-positive cells were observed
in EAE rats. The number of TUNEL-positive RGC was notably
decreased in the low-dose celastrol group compared to the
EAE group. Few TUNEL-positive RGC was found in the
high-dose celastrol group (Figure 7A). Mitochondria-mediated
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FIGURE 7 | Celastrol attenuates ganglion cells apoptosis in the retina of EAE rats. Treatment of celastrol decreased the number of TUNEL-positive cells (A),
upregulated expression of Bcl-2 (B) and downregulated expression of Bax, cleaved-caspase 3 and cleaved-PARP. Scale bar: 100 µm. Data were shown as
mean ± SD, n = 5. ∗∗P < 0.01 versus control group, ##P < 0.01 versus EAE group, ††P < 0.01 versus low dosage of celastrol group.
apoptotic pathway was also investigated in optic nerves. Results
of Western blot analysis revealed that the expression of Bcl-2
was downregulated and the expression of Bax was upregulated
in optic nerve of EAE rats. These changes indicated that the
ratio of Bcl-2/Bax was made a pro-apoptotic shift. Meanwhile,
increased expression of cleaved-caspase-3 and cleaved-PARP
was also observed in EAE rats (Figure 7B). In consistence
with the observation in TUNEL analysis, treatment EAE rats
with celastrol markedly restored these changes, indicating that
celastrol treatment protected RGC from acute EAE.
DISCUSSION
Multiple sclerosis is an autoimmune inflammatory demyelinating
disease of the CNS without effective treatment. Optic nerve
injury occurs early in the development progress of MS
(Hobom et al., 2004). Celastrol is a natural compound that
generally used for anti-inflammation and anti-autoimmunity.
Previous studies have demonstrated that celastrol ameliorated
EAE development by suppressing pathogenic Th17 responses
and inhibiting inflammatory responses in spinal cord and
brain (Abdin and Hasby, 2014; Wang et al., 2015). The
present study designed to evaluate the effects of celastrol
on MS and ON. Using MPB-induced EAE rats, we found
that celastrol attenuated demyelination, inhibited production
of pro-inflammatory cytokines and increased production of
anti-inflammatory cytokines in spinal cord. In addition, we
found the inflammatory response was also suppressed by
celastrol in optic nerve, as well as the apoptosis of RGC
in retina. These results indicate that celastrol alleviates the
neurologic severity of EAE via suppressing demyelination and
inflammation in spinal cord, and attenuates ON by inhibiting
inflammation in optic nerve and preventing RGC apoptosis in
retina.
Spinal cord injury is the primary cause of long-term disability
in MS. Results of magnetic resonance imaging (MRI) detection
show abnormalities in spinal cord in approximate 75% of the
MS patients, and the cervical cord is the most common lesion
site (Kidd et al., 1993; Nijeholt et al., 1998; Lukas et al., 2013).
In addition, a previous MRI study demonstrated that early
spinal cord lesions were predictive in disability in isolated ON
patients converting to MS (Swanton et al., 2009). Inflammation
in the CNS is considered to contribute to the spinal cord injury
including demyelination, axon loss and atrophy in MS and EAE
(Siffrin et al., 2010; Friese et al., 2014). In the present study, from
the results of LFB staining, we found that celastrol significantly
attenuated the demyelination in the spinal cord of EAE rats,
which was consistent with its promoting effects in neurological
function test. Meanwhile, H&E staining illustrated the reduced
inflammatory infiltration in the spinal cord of celastrol-treated
EAE rats. Based on the accepted links between disability, spinal
cord injury and inflammation, we deduced that celastrol could
attenuate neurological dysfunction in EAE rats, which might
be associated with its effects on inhibiting demyelination and
inflammation in the spinal cord.
Multiple sclerosis is an autoimmune disorder of the CNS
and the infiltration of immune cells into the CNS occurs at
the onset of the disease. Although detailed pathogenesis of MS
is not well revealed, it is widely accepted that CD4+ T cells
play important roles in this disease. CD4+ T cells are generally
classified into helper-T-cell (Th)1, Th2, Th17 and regulatory
T cell (Treg) according to the cytokines they secreted (Wan
and Flavell, 2009). INF-γ and IL-17, which are secreted by
Th1 and Th17, respectively, are considered as pro-inflammatory
cytokines. In contrast, IL-4 and IL-10, which are produced by
Th2 and Treg, are considered as anti-inflammatory cytokines.
In normal condition, the activities of these cells of opposite
functions reach a balance. In MS, the balance is broken, the pro-
inflammatory cytokines are over-produced and the secretion of
anti-inflammatory cytokines is suppressed, which induces the
abnormal immune attack into the CNS (Benveniste et al., 2014;
Segal, 2014). In EAE models, T cells are activated by myelin and
migrate to the CNS, which mimics the immune cells infiltration
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as in MS. In the present study, the mRNA expression of INF-γ, IL-
17 was downregulated and the expression of IL-4 was upregulated
in the spinal cord of celastrol-treated EAE rats. This finding is
consistent with the previous study in which celastrol was found
to reduced the percentage of CD4+IL-17+ T cells in spinal cord
(Wang et al., 2015), and indicates that celastrol attenuates spinal
cord injury in EAE through re-balancing the pro-inflammatory
Th1/17 and anti-inflammatory Th2/Treg factors.
Immune responses also play important roles in ON
pathogenesis (Smith et al., 2011; Das et al., 2013). As introduced
above, Th1/Th17 and Th2/Treg cells are also implicated in the
pathological process of ON. In the current investigation, we
determined the mRNA expression of INF-γ, TNF-α and IL-
1β, which are produced by Th1, IL-17, which is produced by
Th17, and IL-4, which is produced by Th2. In line with our
observation in the spinal cord, dramatic increases in Th1 and
Th17 cytokines and decrease in Th2 cytokine were found in
the optic nerve in EAE rats. Treatment of celastrol markedly
reversed this change so that the expression of Th1 and Th17
cytokines was downregulated, while IL-4 was upregulated. We
and others have proved the effects of celastrol on immune
cells regulation, and the present result extends the knowledge
to optic nerve. In the CNS, gliosis, especially microgliosis,
which is induced by the overproduced cytokines and other
factors, is a hallmark of inflammation. Microglia is considered
to be the immune system in the CNS. Microglia activation is
a primary factor in the CNS against various injuries including
inflammation (Kreutzberg, 1996). Our current data show that
celastrol attenuates microgliosis in the optic nerve of EAE
rats.
NF-κB is an important nuclear factor that regulates
transcription of numerous inflammatory and immune-associated
factors. Inhibition of NF-κB has been demonstrated to beneficial
for treating ON in EAE (Das et al., 2013). Celastrol is a potent
natural NF-κB inhibitor (Lee et al., 2006; Nam, 2006) and has
been demonstrated to block NF-κB activation in various diseases
including MS (Wang et al., 2015). The goal of this study was
to extend the understanding of the NF-κB inhibitory effect
of celastrol to optic nerve, and to examine the expression of
NF-κB-regulated inflammatory-associated protein iNOS in EAE
rats. Improper upregulation of iNOS results overproduction
of NO, and the latter may contribute to the cell damage and
myelin loss (Iwahashi et al., 1999; Danilov et al., 2003). We found
that celastrol effectively inhibited NF-κB phosphorylation and
nuclear translocation, and downregulated iNOS expression in
optic nerve. Our results indicate that the anti-inflammatory effect
of celastrol may contribute to its neuroprotective effects on optic
nerve.
Axons damage is a primary pathological feature of MS and
is the major cause of visual loss in this disease. Apoptosis of
RGCs, the neurons that form the axons of optic nerve, has been
found to occur early in the development of the disease in animal
models of EAE (Meyer et al., 2001; Hobom et al., 2004). In the
current study, retina of EAE rats showed obviously increased
apoptotic RGCs, and treatment of celastrol markedly reduced
apoptotic RGCs. In previous studies, apoptosis of RGCs has
been found both before and after optic nerve inflammation in
EAE, which indicates that inflammation is not the only reason
of RGC apoptosis (Hobom et al., 2004; Shindler et al., 2006).
We did not investigate the apoptosis in the very early time point
after MBP immunization, which was a limitation of the present
study. Therefore, inflammation may not the only reason that
responsible for the apoptosis of RGCs in our study. In spite
of this, the anti-inflammatory effect of celastrol may still, at
least partly, contribute to the inhibition of RGCs apoptosis. In
addition, mitochondrial apoptotic pathway, which was regulated
by Bcl-2 family proteins, was also investigated in this study. It
is well accepted that Bcl-2 is an anti-apoptotic protein and Bax
is a pro-apoptotic protein. Generally, the ratio of Bcl-2/Bax is
used to reflect the apoptotic tendency of target organs (Ola et al.,
2011). In our study, treatment of celastrol resulted in upregulated
Bcl-2 and downregulated Bax, which shifted the relation of
these two proteins toward a more pro-survival ratio in RGCs.
Meanwhile, cleaved-caspase 3 and PARP, two important proteins
that mediate apoptosis, were downregulated by celastrol as well.
Our study suggests that celastrol exerts an inhibitory effect on
RGCs apoptosis in EAE rats. This effect may come from both
the indirect effect of anti-inflammation and the direct effect of
apoptotic-associated proteins regulation of celastrol.
Collectively, the present study confirms the neuroprotective
effects of celastrol on EAE models through T cells activities
regulation. In addition, our data indicate that celastrol attenuates
ON in EAE via anti-inflammatory and anti-apoptotic effects.
These findings provide new pre-clinical evidence for the use of
celastrol in treatment of multiple sclerosis.
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